Málaga suspends Victor after a video of the technician’s sexual nature has been disseminated

first_imgVíctor Sánchez del Amo has put in the hands of the police harassment and extortion who is suffering after spreading through social networks orNo supposed video of his sexual nature. Malaga, meanwhile, has decided to suspend him from his duties until the investigation is completed.The coach of Malaga has issued a statement on their social networks informing the fact and reminding users that it is a crime typified by article 197 of the Criminal Code to disseminate personal content without consent. The statement of Víctor Sánchez de Almo pray like this: “I want to report that I am being the subject of a crime against my privacy with harassment and extortion. The matter is in the hands of the police and I entrust myself to follow their instructions. I also want to inform that they share or disseminate an intimate content of anyone without consent it is also a crime, either through social networks or messages or in any other way as established in article 197 of the Criminal Code with penalties for those who disseminate personnel without the consent of the affected person. Thank you for your understanding and support “. The malaguista team does not play this weekend since it was eliminated in Copa del Rey by the Broom (2-0). The next meeting of Malaga is Tuesday, January 14 before the Ponferradina (20:00 hours) and for now, Victor will not be on the bench The Rose Garden.last_img read more

Computer helps researchers tackle multiple flu strains at once

first_imgH1N1. H5N1. H7N9. The influenza virus comes in many varieties and goes by many names. Its diversity is also its greatest asset: the ability to change two proteins on its surface—H and N in shorthand—lets it evade the immune system and complicates the work of drug- and vaccinemakers. Now, researchers report that they’ve used computers to help them target a region of the virus that rarely changes, and they’ve designed a small protein that renders the virus unable to infect cells and cause disease, at least in mice.“It’s a new way to rationally develop antiviral drugs,” says veterinary microbiologist Jürgen Richt at Kansas State University, Manhattan, who was not involved in the study. “It’s a nice paper and I think they’re doing good work, but as always there is more to do.”Today in PLOS Pathogens, scientists report that they’ve designed small molecules to target a particularly vulnerable region of hemagglutinin, one of the two proteins that jut from the viral surface like a flower. They home in on the stem of the flower, a portion of the protein that remains conserved between varied strains of the virus. Scientists previously have shown that antibodies directed at the stem stop a diverse array of influenza viruses from causing an infection, and some are being developed as treatments. But the drug might have an advantage because mouse studies have found that monoclonal antibodies need help from other arms of the immune system that sometimes are compromised in the elderly—the group most vulnerable to influenza virus. Small molecule drugs are also far easier—and cheaper—to manufacture than monoclonal antibodies.  Koday et al., Creative Commons The researchers began with a small protein called HB36.5, which is known to bind to influenza’s hemagglutinin. Using a combination of laboratory assays and computer algorithms, the team tested various mutations in HB36.5, looking for single amino acid changes that would increase how tightly the protein bound to a diverse group of hemagglutinins. Eventually the tests converged on a protein with nine mutations, which the researchers dubbed HB36.6.The scientists gave HB36.6 to a group of mice both before and after infecting them with a lethal dose of flu virus. When given prophylactically, all of the mice survived and lost less weight than control animals infected with the same virus. When administered after infection, the protein was less effective, but still significantly reduced death and weight loss. Further testing showed that HB36.6 shuts down the virus without help from the immune system. Sign up for our daily newsletter Get more great content like this delivered right to you! Country Emailcenter_img Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Click to view the privacy policy. Required fields are indicated by an asterisk (*) Deborah Fuller, a microbiologist at the University of Washington, Seattle, who led the study, notes that HB36.6 is still a very long way from the pharmacy shelf. “This is a proof of concept,” Fuller says. “Everything works in mice, it seems. They’re not always the best predictor of what’s going to work in humans.” Still, Fuller and her team hope to move into clinical trials soon.Even if HB36.6 doesn’t prove its worth in human studies, the researchers contend it opens the door to a new class of computer-generated antiviral drugs. Aside from operating independent of the immune system, the approach may make it more difficult for the virus to become resistant to drugs. Like the combination therapies used to treat HIV, scientists could design a suite of slightly different proteins that targets the hemagglutinin stem region, making it more difficult for the virus to dodge the drug with a single mutation.Richt agrees the results are encouraging, but points out that HB36.6 may only have limited usefulness in the real world. Flu symptoms typically occur a few days after infection, and HB36.6 lost about half its effectiveness when administered 24 hours after infection in mice. “If we have a pandemic and everybody is nervous, and they want to take it as a prophylactic, that might be ok,” Richt says. But the ideal flu drug would work against all strains when symptoms surface, which remains a tall order.last_img read more